LakePharma to Showcase Antibody Discovery and Protein Engineering Expertise at PEGS Boston 2016

BELMONT, Calif.–(BUSINESS WIRE)–LakePharma, Inc. the leading protein engineering CRO dedicated to
providing integrated biologics discovery and development services, will
present key data at the upcoming PEGS 2016 Protein Engineering Summit in
the form of several case studies highlighting the challenges that arise
from the multiple domain nature of fusion protein therapeutics.
Specifically, Hua Tu, Ph.D., LakePharma’s Chairman and CEO, will share
data for the design, engineering, bioanalytical characterization and
manufacturability assessment of Fc fusions and bispecific antibodies.
Company scientists will also present a poster detailing a tandem mass
spectrometry approach to proteomic sequencing that enables the accurate
determination of an antibody’s primary sequence when the source
hybridoma is unavailable. In addition to revealing the full sequence of
an important antibody, their approach enabled the engineering of the
antibody to improve its production by CHO cells, as well as its
performance as a purification reagent.
Details on Presentation and Poster Sessions

• Overcoming Multiple Domain Challenges of Fc Fusions and Fab Fusion
  Bispecific Antibodies
  Speaker: Hua Tu, Chairman and CEO,
  LakePharma
  Day: Tuesday April 26, 2016
  Time: 3:05 – 3:35 pm
  ET
  Stream: Bioconjugates
  Track: Fusion Protein Therapeutics:
  Engineering Enzymes

• Poster A63: Proteomic Sequencing and Resurrection of a Monoclonal
  Antibody
  Authors: Natalie Castellana, Digital Proteomics;
  Kexin Huang and Hua Tu, LakePharma
  Presentation: April 25 and 26

“As specialists in antibody discovery and protein engineering, our
bi-coastal team is well positioned to offer pharmaceutical and
biotechnology companies the most comprehensive continuum of services to
enhance the quality and speed of their biologics discovery and
development,” said Dr. Tu.
Celebration of Merger with Blue Sky BioServices
The company invites all PEGS Boston attendees to join the LakePharma
team at a cocktail party celebrating LakePharma’s acquisition of Blue
Sky BioServices on the evening of Tuesday April 26 from 4:30 to 6:30 pm
at Jerry Remy’s Seaport location. For more details on this event, please
visit either of our PEGS booths, #241 and #319.
“The joining of LakePharma and Blue Sky BioServices at the end of March
has created the U.S. biotech and pharmaceutical industry’s largest CRO
dedicated to biologics,” said Dr. Tu. “Together, our comprehensive
capabilities in antibody development, protein expression and
characterization, molecular biology, and protein analytics provide a
full continuum of services for discovery and early stage biotherapeutic
development. Moreover, with four facilities in the San Francisco Bay
Area and Cambridge/Boston areas, we’re based right where our clients are
— in the nation’s greatest biotech hubs.”
About LakePharma
LakePharma is a contract research organization (CRO) dedicated to
serving the discovery research and protein engineering needs of
companies engaged in the development of biotherapeutics. The company has
assembled the United States’ most comprehensive suite of technologies
and expertise to offer a large continuum of services for antibody and
protein discovery and engineering, cell line creation, and protein
analytics. Clients may access our services individually or as a fully
integrated “soup to nuts” solution for all of their molecular biology,
protein chemistry, cell line, assay, and production scale-up needs.
Moreover, LakePharma provides superior client services and sophisticated
software to provide real-time access to project data via a secure
cloud-based portal, Datasystems. For more information, please visit www.lakepharma.com.